Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
DementiaParkinson Disease
Interventions
DRUG

Quetiapine

Trial Locations (21)

10032

Columbia University, Alzheimer's Disease Research Center, New York

11219

Maimonides Medical Center, Brooklyn

12205

Parkinson's Disease and Movement Disorders Center, Albany Medical College, Albany

13210

Syracuse VA Medical Center, Syracuse

14620

University of Rochester Medical Center, Alzheimer's Disease Center, Rochester

30322

Emory University, Alzheimer's Disease Center, Atlanta

30912

Medical College of Georgia, Augusta

60612

Rush University Medical Center, Chicago

62702

Southern Illinois University, School of Medicine, Springfield

89102

University of Nevada, Las Vegas

90822

VA Healthcare System Long Beach, Long Beach

92037

University of California, San Diego, Alzheimer's Disease Center, La Jolla

94304

Stanford/VA Aging Clinical Research Center, Department of Psychiatry & Behavioral Sciences, Palo Alto

35233-0017

University of Alabama at Birmingham, Alzheimer's Disease Research Center, Birmingham

90095-1769

University of California at Los Angeles, Alzheimer's Disease Center, Los Angeles

01730

E. N. Rogers Memorial Veterans Hospital, Bedford

15213-2593

University of Pittsburgh, Alzheimer's Disease Research Center, Pittsburgh

75390-9070

University of Texas Southwestern Medical Center at Dallas, Alzheimer's Disease Center, Dallas

05201

Memory Clinic at Southwestern Vermont Medical Center, Bennington

05401

Fletcher Allan Health Care, Inc., Burlington

98108-1597

University of Washington at Seattle, Alzheimer's Disease Research Center, Seattle

All Listed Sponsors
lead

National Institute on Aging (NIA)

NIH

NCT00043849 - Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) | Biotech Hunter | Biotech Hunter